Fulcrum Therapeutics (Fulcrum Therapeutics) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Days Sales Outstanding?

Fulcrum Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $0.00 Mil. Fulcrum Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.87 Mil. Hence, Fulcrum Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Fulcrum Therapeutics's Days Sales Outstanding or its related term are showing as below:

FULC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.69 Med: 82.74 Max: 143.88
Current: 1.69

During the past 7 years, Fulcrum Therapeutics's highest Days Sales Outstanding was 143.88. The lowest was 1.69. And the median was 82.74.

FULC's Days Sales Outstanding is ranked better than
99.21% of 889 companies
in the Biotechnology industry
Industry Median: 71.03 vs FULC: 1.69

Fulcrum Therapeutics's Days Sales Outstanding declined from Dec. 2022 (1.73) to Dec. 2023 (0.00).

Fulcrum Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Fulcrum Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics Days Sales Outstanding Chart

Fulcrum Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

82.74

42.86

143.88

Fulcrum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															1.73	-	-	-	-

Competitive Comparison of Fulcrum Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Fulcrum Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulcrum Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's Days Sales Outstanding falls into.

Fulcrum Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Fulcrum Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	2.805	*	365
=	0					/	2.805	*	365
=	0.00

Fulcrum Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.871	*	365 / 4
=	0					/	0.871	*	365 / 4
=	0.00

Fulcrum Therapeutics (NAS:FULC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Fulcrum Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulcrum Therapeutics (Fulcrum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Landsdowne Street, Cambridge, MA, USA, 02139

Website

https://www.fulcrumtx.com

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Executives

Alan A Musso	officer: Chief Financial Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir	director, officer: See Remarks	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Greg Tourangeau	officer: Controller	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould	director, officer: President & CEO	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo	officer: Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii	officer: Chief Operating Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu	officer: Chief Financial Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart	officer: Chief Operating Officer	C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham	officer: Chief Scientific Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson	officer: VP Finance & Accounting	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139